Sitagliptin Does Not Directly Cause AKI
Sitagliptin itself does not cause acute kidney injury and is considered cardiovascular and renal-safe in patients with type 2 diabetes, including those with pre-existing renal impairment. 1, 2
Evidence from Guidelines and Drug Labels
The most recent American Diabetes Association guidelines (2025) classify DPP-4 inhibitors, including sitagliptin, as having "neutral" effects on renal outcomes with "unknown" risk for kidney injury. 1 The guidelines note that pancreatitis has been reported but causality has not been established, and make no mention of AKI as a recognized adverse effect. 1
Sitagliptin requires dose adjustment based on kidney function but is safe to use across all stages of chronic kidney disease, including end-stage kidney disease and dialysis. 1 The dosing is:
- 100 mg daily if eGFR > 50 mL/min/1.73 m²
- 25 mg daily if eGFR 30-50 mL/min/1.73 m²
- 25 mg daily if eGFR < 30 mL/min/1.73 m² 1
The FDA label for sitagliptin does not list AKI as a contraindication or warning. 3
Clinical Trial Evidence
The most robust clinical evidence comes from the Sita-Hospital trial (2017), a multicenter randomized controlled trial of 277 hospitalized patients with type 2 diabetes. 4 This study found no difference in AKI rates between sitagliptin-treated patients (5%) versus basal-bolus insulin controls (4%), demonstrating that sitagliptin does not increase AKI risk even in the vulnerable hospitalized population. 4
A large retrospective claims analysis of 491,539 patients (2012) found no association between sitagliptin use and increased risk of acute renal failure (HR 1.17, CI 0.82-1.65, p = 0.39). 5
The most recent literature review (2025) confirms that sitagliptin is cardiovascular and renal-safe in patients with type 2 diabetes, even those with obesity, advanced age, renal impairment, and pre-existing cardiovascular disease. 2
Rare Exceptions: Drug Interactions and Allergic Reactions
While sitagliptin itself does not cause AKI, two rare scenarios exist:
Drug Interaction with Statins
When sitagliptin is combined with statins (particularly simvastatin, atorvastatin, or lovastatin), there are case reports of rhabdomyolysis leading to secondary AKI. 6, 7 This interaction appears to occur primarily in:
- Elderly patients
- Those with underlying chronic kidney disease
- Patients with vitamin D deficiency 6
If prescribing sitagliptin to patients on statins, monitor for muscle pain, weakness, and elevated creatine kinase levels, particularly in the first few weeks of combination therapy. 7
Acute Tubulointerstitial Nephritis (ATIN)
A single case report (2016) documented biopsy-proven acute tubulointerstitial nephritis attributed to sitagliptin, representing a rare allergic reaction of the kidney. 8 This is an exceedingly uncommon idiosyncratic reaction, not a direct toxic effect.
Comparative Context
Recent comparative effectiveness studies demonstrate that SGLT2 inhibitors provide superior kidney protection compared to DPP-4 inhibitors like sitagliptin, with lower risks of both chronic kidney disease progression and AKI. 9, 10 However, this does not mean sitagliptin causes AKI—rather, SGLT2 inhibitors actively prevent it while sitagliptin maintains a neutral safety profile. 1, 2
Clinical Bottom Line
Sitagliptin can be safely prescribed without concern for causing AKI. 4, 5, 2 Monitor patients on concurrent statin therapy for signs of rhabdomyolysis, especially elderly patients with pre-existing kidney disease. 6, 7 If unexplained AKI develops in a patient on sitagliptin, consider the rare possibility of allergic tubulointerstitial nephritis and evaluate for other more common causes first. 8